

## LETTERS TO THE EDITOR

6. Srivastava SC, Straub RF. Evaluation of heparin and anticoagulant citrate dextrose in the preparation of technetium-99m-red blood cells with UltraTag® RBC kit. [Letter] *J Nucl Med* 1992;33:307-308.
7. Wolfangel RG. Evaluation of heparin and anticoagulant citrate dextrose in the preparation of technetium-99m-red blood cells with UltraTag® RBC kit. [Letter] *J Nucl Med* 1992;33:308.
8. Wilson ME, Hung JC. Evaluation of heparin and anticoagulant citrate dextrose in the preparation of technetium-99m-red blood cells with UltraTag® RBC kit. [Letter] *J Nucl Med* 1992;33:306-307.
9. Colombetti LG, Barnes WE. Effect of chemical and radiochemical impurities from eluants on <sup>99m</sup>Tc-labeling efficiency. *Nuklearmedizin* 1977;16:271-274.
10. Molinski VJ. A review of <sup>99m</sup>Tc generator technology. *Int J Appl Radiat Isot* 1982;33:811-819.

### AN ACCURATE AND INEXPENSIVE GAMMA CAMERA-BASED SYSTEM FOR WIPE TESTING

**To the Editor:** I read the article, "An Accurate and Inexpensive Gamma Camera-Based System for Wipe Testing," by Curtis B. Caldwell (*J Nucl Med Technol* 1997;25:201-204) with a great deal of interest. I like the concept of using a damaged collimator that is stashed away in an out-of-the-way corner to count wipe tests and save the technologist time when time is at a premium. However, there may be an error in the methodology.

I could not discern from the article if wipe efficiency (i.e., the ratio of radioactive atoms on a contaminated surface that are physically transferred to the wipe) was taken into account. If wipe efficiency was not taken into account and one assumes the conven-

tional ratio of 0.1, then the reported MDAs are underestimated by a factor of 10 and the cited regulations are not met. If the error is real (and I am not certain that it is), I also wonder if this is a widespread error in methodology within the nuclear medicine community. Apparently the error was not caught during the review process. I would not like anyone to be cited for a violation of the regulations when the concept of using a damaged collimator for wipe testing is really quite excellent.

**Dave Horn, CNMT**  
Powhatan, Virginia

**Reply:** Dave Horn raises an important point regarding the need to incorporate a wipe efficiency or collection factor into the calculation of removable activity. This factor was not taken into account in my paper (1). I did not make it clear that I was calculating minimum detectable activity (MDA) on the wipe, to which one must apply the collection factor to derive an estimate of removable activity. Note that one must be aware of the vagaries of local regulations in this matter. For example, when reporting leak tests of sealed sources in Canada, one need not take into account a collection factor. In my experience in Canada, the federal regulatory body has not enforced the use of a collection factor for contamination monitoring in nuclear medicine (despite the fact that Canadian regulations require the use of a collection factor). If the collection factor has

not been determined experimentally, it should be assumed to be 0.1, as noted by Mr. Horn. Note that there have been few publications regarding collection factors for nuclear medicine radiopharmaceuticals (2).

If the collection factor must be assumed to be 0.1, then it would be necessary to modify the acquisition time used to ensure that less than 50 Bq per 100 cm<sup>2</sup> of removable contamination was present (i.e., 5 Bq on the wipe). In order to obtain an MDA less than 5 Bq (on the wipe) in a reasonable counting time, it would be necessary to perform the testing when the background count is low (i.e., after normal working hours). For our set-up, a 10-min acquisition time in "after hours" background conditions is sufficient to reduce the MDA to below 5 Bq (on the wipe) for all radioisotopes tested. In our department a much longer acquisition time would be required during normal working hours due to the higher background count rate.

I certainly agree with Mr. Horn that I would not wish anyone to be cited for a violation of regulations due to unclear writing on my part.

**Curtis B. Caldwell, PhD, MCCPM**  
Department of Medical Imaging  
Sunnybrook Health Science Center  
Toronto, Ontario, Canada

#### References

1. Caldwell CB. An accurate and inexpensive gamma camera-based system for wipe testing. *J Nucl Med Technol* 1997;25:201-204.
2. Scott LE, Gibson CJ. Wipe tests to assess <sup>99m</sup>Tc surface contamination: effects of surface type, swab type and chemical form. *Nucl Med Comm* 1991;12:127-133.